The results are really good, normally when a drug has a successful effect phase 2 there’s still a lot of doubt about passing a phase 3, but this is where the success of trofinitide in its phase 3 trial will do away with a lot of doubt people may have of this passing phase 3 as well.
NEU will also have the benefit of reworking the trial design if desired so all secondary endpoints are met - but this may just happen anyway with an increase in patient numbers
Ann: P2 trial shows significant improvements in Phelan-McDermid, page-40
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$12.54 |
Change
0.280(2.28%) |
Mkt cap ! $1.559B | |||
| Open | High | Low | Value | Volume |
| $12.52 | $12.73 | $12.26 | $8.152M | 652.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 665 | $12.50 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.55 | 235 | 1 |
View Market Depth
| Last trade - 16.10pm 24/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |